Group 1: Beida Pharmaceutical - In 2024, Beida Pharmaceutical achieved operating revenue of 2,891.95 million yuan, a year-on-year increase of 17.74%, and a net profit attributable to shareholders of 402.57 million yuan, up 15.67% year-on-year [1] - The company has launched five new drugs, including Acetylcysteine, Ensartinib capsules, Bevacizumab, and others, with Beimu approved by the FDA and included in the NCCN guidelines [1] - R&D investment for 2024 is 717 million yuan, accounting for 24.80% of revenue, with multiple new drug developments progressing smoothly [1] Group 2: East China Pharmaceutical - East China Pharmaceutical is actively advancing product R&D and market layout across multiple fields, with GLP-1 series products entering Phase III clinical trials, expecting significant results by 2025 [2] - The company has several innovative products in the ADC and PROTAC fields, with some already in clinical stages [2] - East China Pharmaceutical is confident in the overseas medical beauty market and is actively pursuing overseas registration for its medical beauty products [2]

Group 1: Financial Performance - The company achieved a revenue of 289,195.01 million yuan in 2024, representing a year-on-year growth of 17.74% [2] - The net profit attributable to shareholders was 40,256.93 million yuan, a year-on-year increase of 15.67% [2] - The net profit excluding non-recurring items reached 40,983.41 million yuan, showing a significant growth of 55.92% [2] - Accounts receivable balance decreased by 65.62% year-on-year, with accounts receivable turnover days reduced by 29 days [2] - The net cash flow from operating activities was 91,117.22 million yuan [2] Group 2: Product Development and Market Position - Five new drugs have been launched, including innovative treatments for lung cancer and kidney cancer [3][4] - The drug Beimenna received FDA approval in December 2024 and was recommended by the NCCN guidelines, marking it as the first Chinese original innovative drug in this category [4] - The company is actively promoting the commercialization of Beidan, leveraging its clinical research and market promotion teams [4] - The drug Fumina has shown promising clinical potential in ophthalmology, with ongoing II phase clinical studies [5] Group 3: Research and Development - R&D investment for 2024 was 71,717.78 million yuan, accounting for 24.80% of total revenue [6] - The company is focusing on key R&D projects, with several innovative drug applications under review by the NMPA [6] - Collaboration with clinical oncology experts is ongoing to support investigator-initiated clinical research projects [6] Group 4: Strategic Partnerships - The company has established strategic collaborations with various organizations to enhance its R&D pipeline [7][8] - A partnership with EyePoint for the development of an ophthalmic drug has shown positive results in clinical trials [8] - The company is pursuing a dual strategy of project introduction and self-innovation to expand its treatment options [8] Group 5: Innovation Ecosystem - The company is building an innovation ecosystem to promote collaboration and resource sharing among various stakeholders [9] - A partnership with He Yuan Bio for the commercialization of a plant-derived human serum albumin injection has been established [9] - Investment in Repu Morning Creation for stem cell therapy development is underway, with clinical trials for core products already initiated [10]

Group 1: Participants Overview - The report lists a total of 148 participants from various investment and asset management firms [1][2][3][4] - Participants include representatives from well-known firms such as Goldman Sachs, Manulife, and Temasek Holdings [1][2][3][4] Group 2: Company Representation - The participants represent a diverse range of companies, including domestic and international firms [1][2][3][4] - Notable companies include Huatai Asset Management, China Life Asset Management, and CICC [1][2][3][4] Group 3: Investment Focus - The report indicates a strong interest in pharmaceutical and healthcare investments, as evidenced by the presence of multiple healthcare-focused firms [1][2][3][4] - Several participants are from firms specializing in medical and pharmaceutical investments, highlighting the sector's significance [1][2][3][4] Group 4: Event Context - The event serves as a platform for investor communication and networking among key industry players [1][2][3][4] - The diverse representation suggests a broad interest in collaboration and investment opportunities within the sector [1][2][3][4]

Market Performance - On April 17, 2025, the pharmaceutical sector had a change of +0.04%, outperforming the CSI 300 index by 0.06 percentage points, ranking 16th among 31 sub-industries in the Shenwan classification [1] - Among sub-industries, medical devices (+0.98%), pharmaceutical distribution (+0.40%), and offline pharmacies (+0.35%) performed well, while other bioproducts (-0.57%), vaccines (-0.48%), and blood products (-0.22%) lagged [1] - Top three gainers in individual stocks were Kangpeng Technology (+20.00%), Nuosige (+10.06%), and Yisheng Pharmaceutical (+10.03%); top three losers were Changyao Holdings (-6.33%), Hasanlian (-5.26%), and Shouyao Holdings (-4.81%) [1] Industry News - On April 17, 2025, Eli Lilly announced that its oral GLP-1 receptor agonist Orforglipron achieved statistically significant positive results in a key Phase III clinical trial (ACHIEVE-1) [2] - The study evaluated the safety and efficacy of Orforglipron compared to a placebo in adults with type 2 diabetes who had poor blood sugar control through diet and exercise alone [2] - Orforglipron is a research-based, once-daily oral small molecule (non-peptide) GLP-1 receptor agonist that can be taken at any time of the day without food and drink restrictions [2] Company News - Huayuan Bio (300401) reported Q1 2025 revenue of 326 million yuan, a year-on-year decrease of 1.18%, with net profit attributable to the parent company at 97 million yuan, a year-on-year increase of 5.50%, and a non-recurring net profit of 88 million yuan, up 44.42% year-on-year [3] - Puluo Pharmaceutical (000739) reported Q1 2025 revenue of 2.73 billion yuan, a year-on-year decrease of 14.63%, with net profit attributable to the parent company at 249 million yuan, a year-on-year increase of 1.98%, and a non-recurring net profit of 206 million yuan, down 14.05% year-on-year [3] - Sanbo Brain Science (301293) reported 2024 revenue of 1.43 billion yuan, a year-on-year increase of 8.84%, with net profit attributable to the parent company at 105 million yuan, a year-on-year increase of 34.24%, and a non-recurring net profit of 94 million yuan, up 0.77% year-on-year [3] - Betta Pharmaceuticals (300558) reported 2024 revenue of 2.89 billion yuan, a year-on-year increase of 17.74%, with net profit attributable to the parent company at 403 million yuan, a year-on-year increase of 15.67%, and a non-recurring net profit of 410 million yuan, up 55.92% year-on-year [3]

Group 1 - The company has launched five new drugs by 2024, including its first innovative drug, EGFR-TKI Alectinib (brand name: Kaimena®), ALK inhibitor Ensartinib (brand name: Beimana®), third-generation EGFR inhibitor BPI-D0316 (brand name: Saimena®), and targeted drug Vorolanib (brand name: Fumeina®) [1] - The company is currently reviewing the market application for its new breast cancer drug BPI-16350 (brand name: Kangmeina®) and a strategic collaboration product, which is expected to contribute to new revenue growth in the future [1] - The company has established a robust revenue growth and cash flow through academic promotion, commercial operation, and lifecycle cost control, ensuring a positive cycle of "R&D - commercialization - reinvestment" for orderly advancement of its subsequent R&D pipeline [1] Group 2 - The company's internationalization strategy is accelerating, with the application for Beimana's first-line indication approved by the FDA in December 2024, and the EMA's application process officially initiated [2] - The company invested 717 million yuan in R&D in 2024, accounting for 24.80% of its operating revenue, focusing resources on key R&D projects [2] - Multiple innovative drug INDs have been approved during the reporting period, including BPI-520105 tablets, BPI-221351 tablets, EYP-1901 intravitreal implant, CFT8919 capsules, and BPI-452080 tablets [2]

Group 1 - The actual controller, chairman, and CEO of Juran Smart Home, Wang Linpeng, has been detained, but the company's operations remain normal and unaffected [1] - Juran Smart Home reported a total revenue of 12.966 billion yuan in 2024, a decrease of 4.04% year-on-year, and a net profit of 883 million yuan, down 32.08% year-on-year, primarily due to economic fluctuations and increased competition in the home furnishing market [3][4] Group 2 - China Bank plans to raise up to 165 billion yuan through a private placement of A-shares, with the funds aimed at increasing its core tier one capital [4] - The issuance price for China Bank's shares is set at 6.05 yuan per share, which is 80% of the average trading price over the previous 20 trading days [4] - The Bank of Communications also plans to raise up to 120 billion yuan through a private placement, with the funds also designated for core tier one capital [5] Group 3 - SANY Heavy Industry reported a total revenue of 78.383 billion yuan in 2024, an increase of 5.9% year-on-year, and a net profit of 5.975 billion yuan, up 31.98% year-on-year [6][7] - The company's international main business revenue reached 48.513 billion yuan, accounting for 63.98% of total revenue, with significant growth in various regions [6][8] - SANY Heavy Industry has established 37 lighthouse factories and is recognized for its advanced smart manufacturing capabilities [8] Group 4 - East China Pharmaceutical achieved a total revenue of 41.906 billion yuan in 2024, a growth of 3.16%, and a net profit of 3.512 billion yuan, up 23.72% year-on-year [10][11] - The company has a robust pipeline of over 80 innovative drugs, focusing on diabetes and oncology [11][12] Group 5 - EVE Energy reported a total revenue of 48.615 billion yuan in 2024, a slight decrease of 0.35%, with a net profit of 4.076 billion yuan, an increase of 0.63% [13][14] - The company has seen significant growth in its energy storage business, with a shipment volume of 50.45 GWh, a year-on-year increase of 91.90% [15] Group 6 - China Unicom reported a revenue of 103.35 billion yuan in Q1 2025, a growth of 3.9%, and a net profit of 2.61 billion yuan, up 6.5% year-on-year [19] - Lens Technology achieved a revenue of 17.063 billion yuan in Q1 2025, a growth of 10.10%, with a net profit of 429 million yuan, up 38.71% year-on-year [20] Group 7 - Fuyao Glass reported a revenue of 9.910 billion yuan in Q1 2025, a growth of 12.16%, with a net profit of 2.030 billion yuan, up 46.25% year-on-year [21] - Zhuye Group reported a revenue of 4.803 billion yuan in Q1 2025, a growth of 8.50%, with a net profit of 277 million yuan, up 74.07% year-on-year [23] Group 8 - Cailong Technology reported a net profit growth of 87.55% in 2024, with total revenue of 11.664 billion yuan [32] - Ziyan Food reported a revenue of 3.363 billion yuan in 2024, with a net profit growth of 4.5% [33] Group 9 - Shunyi Environmental reported a revenue of 12.678 billion yuan in 2024, with a net profit growth of 41.58% [35] - Shougang Group turned a profit in Q1 2025, reporting a revenue of 26.533 billion yuan, down 10.18%, with a net profit of 328 million yuan [36] Group 10 - Keda Li reported a revenue of 12.030 billion yuan in 2024, with a net profit growth of 22.55% [38] - Betta Pharmaceuticals reported a revenue of 2.892 billion yuan in 2024, with a net profit growth of 15.67% [40] Group 11 - New Australia reported a revenue of 4.841 billion yuan in 2024, with a net profit growth of 5.96% [41] - Fawer reported a revenue of 16.468 billion yuan in 2024, with a net profit growth of 11.93% [42] Group 12 - Zhongwei Company reported a revenue of 9.065 billion yuan in 2024, with a net profit decrease of 9.53% [43] - Changying Precision reported a revenue of 16.934 billion yuan in 2024, with a net profit growth of 800% [44] Group 13 - Stanley reported a revenue of 10.263 billion yuan in 2024, with a net profit growth of 17.89% [45] - Puyang reported a revenue of 5.192 billion yuan in 2024, with a net profit decrease of 45.48% [46] Group 14 - Huangshi Group received a notice of administrative penalty for failing to disclose significant contracts, with potential fines for the company and responsible individuals [47] - Baosteel announced plans to acquire a 49% stake in Maanshan Steel through a combination of cash purchases and capital increases, with an estimated total investment of 9 billion yuan [48][49] Group 15 - Shengquan Group reported a revenue of 2.459 billion yuan in Q1 2025, with a net profit growth of 50.46% [50]

贝达药业股份有限公司 审计报告及财务报表 二○二四年度 贝达药业股份有限公司 审计报告及财务报表 （2024 年 01 月 01 日至 2024 年 12 月 31 日止） | | 目录 | 页次 | | --- | --- | --- | | 一、 | 审计报告 | 1-5 | | 二、 | 财务报表 | | | | 合并资产负债表和母公司资产负债表 | 1-4 | | | 合并利润表和母公司利润表 | 5-6 | | | 合并现金流量表和母公司现金流量表 | 7-8 | | | 合并所有者权益变动表和母公司所有者权益变动表 | 9-12 | | | 财务报表附注 | 1-110 | 审 计 报 告 信会师报字[2025]第 ZF10183 号 贝达药业股份有限公司全体股东： 一、 审计意见 我们审计了贝达药业股份有限公司（以下简称贝达药业）财务报 表，包括 2024 年 12 月 31 日的合并及母公司资产负债表，2024 年度 的合并及母公司利润表、合并及母公司现金流量表、合并及母公司所 有者权益变动表以及相关财务报表附注。 我们认为，后附的财务报表在所有重大方面按照企业会计准则的 规定编制，公允反映了 ...

贝达药业股份有限公司 内部控制审计报告 2024 年度 内部控制审计报告 信会师报字[2025]第 ZF10184 号 贝达药业股份有限公司全体股东： 按照《企业内部控制审计指引》及中国注册会计师执业准则的相 关要求，我们审计了贝达药业股份有限公司（以下简称"贝达药业"） 2024 年 12 月 31 日的财务报告内部控制的有效性。 一、企业对内部控制的责任 按照《企业内部控制基本规范》、《企业内部控制应用指引》、《企 业内部控制评价指引》的规定，建立健全和有效实施内部控制，并评 价其有效性是贝达药业董事会的责任。 二、注册会计师的责任 我们的责任是在实施审计工作的基础上，对财务报告内部控制的 有效性发表审计意见，并对注意到的非财务报告内部控制的重大缺陷 进行披露。 三、内部控制的固有局限性 内部控制具有固有局限性，存在不能防止和发现错报的可能性。 此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策 和程序遵循的程度降低，根据内部控制审计结果推测未来内部控制的 有效性具有一定风险。 内控审计报告 第 1 页 四、财务报告内部控制审计意见 我们认为，贝达药业于 2024 年 12 月 31 日按照《企 ...

舆情管理制度 贝达药业股份有限公司 舆情管理制度 第一章 总则 第一条 为提高贝达药业股份有限公司（以下简称"公司"）应对各类舆情 的能力，建立快速反应和应急处置机制，及时、妥善处理各类舆情对公司股价、 商业信誉及正常生产经营活动造成的影响，切实保护投资者合法权益，根据法律 法规、规范性文件及《贝达药业股份有限公司章程》（以下简称"《公司章程》"） 的相关规定，制定本制度。 （一）决定启动和终止舆情处理工作的相关事项； 第二条 本制度所称"舆情"包括： （一）报刊、电视、网络等媒体对公司及子公司进行的负面报道； （二）社会上存在的已经或将给公司及子公司造成不良影响的传言或信息； （三）可能或已经影响社会公众投资者投资取向，造成公司股价异常波动的 信息； （四）其他涉及公司信息披露且可能对公司证券及其衍生品交易价格产生较 大影响的信息。 第二章 舆情管理的组织体系及其工作职责 第三条 公司应对各类舆情实行统一领导、统一组织、快速反应、协同应对。 第四条 公司成立舆情管理工作领导小组（以下简称"舆情工作组"），由 公司董事长任组长，董事会秘书、舆情相关公司高级管理人员和企业文化和对外 联络办公室（以下简称"企联办 ...

（肖佳佳） 作为贝达药业股份有限公司（以下简称"公司"）的独立董事，2024 年度本 人严格按照《中华人民共和国公司法》《中华人民共和国证券法》《上市公司独 立董事管理办法》《独立董事和审计委员会履职手册》《上市公司独立董事履职 指引》等法律法规、规范性文件及《贝达药业股份有限公司章程》的规定，本着 客观、公正、独立的原则勤勉尽责、独立履职，在董事会中发挥参与决策、监督 制衡、专业咨询作用，切实维护公司整体利益和全体股东的合法权益。现将本人 2024 年度履行独立董事职责的情况报告如下： 一、独立董事的基本情况 本人肖佳佳，1983 年 10 月生，英国谢菲尔德大学法学硕士。2019 年 3 月至 2024 年 2 月，本人任北京观韬中茂（杭州）律师事务所合伙人；2024 年 3 月至 今，本人任北京竞天公诚（杭州）律师事务所合伙人。本人曾任浙江凯麦律师事 务所主办律师、北京观韬中茂（杭州）律师事务所主办律师、杭州市律师协会公 司与证券专业委员会委员、浙江省律师协会第二届环境与资源保护专业委员会秘 书长，擅长境内外上市、重组及再融资、私募融资、跨境并购、外商直接投资、 私募基金、股权激励等公司证券业务。目前， ...